Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Anti-PEG antibodies have been reported to mediate the accelerated clearance of PEG-conjugated proteins and liposomes, all of which contain methoxyPEG (mPEG). The goal of this research was to assess the role of the methoxy group in the immune responses to mPEG conjugates and the potential advantages of replacing mPEG with hydroxyPEG (HO-PEG). Rabbits were immunized with mPEG, HO-PEG, or t-butoxyPEG (t-BuO-PEG) conjugates of human serum albumin, human interferon-α, or porcine uricase as adjuvant emulsions. Assay plates for enzyme-linked immunosorbent assays (ELISAs) were coated with mPEG, HO-PEG, or t-BuO-PEG conjugates of the non-cross-reacting protein, porcine superoxide dismutase (SOD). In sera from rabbits immunized with HO-PEG conjugates of interferon-α or uricase, the ratio of titers of anti-PEG antibodies detected on mPEG-SOD over HO-PEG-SOD ("relative titer") had a median of 1.1 (range 0.9-1.5). In contrast, sera from rabbits immunized with mPEG conjugates of three proteins had relative titers with a median of 3.0 (range 1.1-20). Analyses of sera from rabbits immunized with t-BuO-PEG-albumin showed that t-butoxy groups are more immunogenic than methoxy groups. Adding Tween 20 or Tween 80 to buffers used to wash the assay plates, as is often done in ELISAs, greatly reduced the sensitivity of detection of anti-PEG antibodies. Competitive ELISAs revealed that the affinities of antibodies raised against mPEG-uricase were c. 70 times higher for 10 kDa mPEG than for 10 kDa PEG diol and that anti-PEG antibodies raised against mPEG conjugates of three proteins had >1000 times higher affinities for albumin conjugates with c. 20 mPEGs than for analogous HO-PEG-albumin conjugates. Overall, these results are consistent with the hypothesis that antibodies with high affinity for methoxy groups contribute to the loss of efficacy of mPEG conjugates, especially if multiply-PEGylated. Using monofunctionally activated HO-PEG instead of mPEG in preparing conjugates for clinical use might decrease this undesirable effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was found that the methoxy group of the mPEG-protein contributed to a significantly higher immune response than that of hydroxy group of HO-PEG.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [81]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Ansar Ahmed, S., Gogal, R. M., & Walsh, J. E. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90396-4 · Cited by 1,359
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Kitamura, T., Tange, T., Terasawa, T., Chiba, S., Kuwaki, T., Miyagawa, K., Piao, Y., Miyazono, K., Urabe, A., & Takaku, F. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041400219 · Cited by 784
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
Research works printed but not linked: 4
- Środa K., 2005, Cell. Mol. Biol. Lett., 10, 37
- Porstmann B., 1981, J. Clin. Chem. Clin. Biochem., 19, 435
- Behr-Gross M.-E., 2007, Pharmeuropa Bio., 2007, 49
- Booth C., 2009, Biologics, 3, 349
Cited by
Items 101–185 of 185
Polypeptides with High Zwitterion Density for Safe and Effective Therapeutics
Zhang, P., Jain, P. R., Tsao, C., Yuan, Z., Li, W., Li, B., Wu, K., Hung, H., Lin, X., & Jiang, S. (2018) · Angewandte Chemie · doi:10.1002/ange.201802452 · Cited by 20
Ando, H., Lila, A. S. A., Kawanishi, M., Shimizu, T., Okuhira, K., Ishima, Y., & Ishida, T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.002 · Cited by 18
Jia, Y., Fernandez, A., & Sampath, J. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c01289 · Cited by 17
Antigenicity Extension: A Novel Concept Explained by the Immunogenicity of PEG
Shiraishi, K., & Yokoyama, M. (2024) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.4c00042 · Cited by 21
“26,27 These studies further revealed that tert -butoxy-terminated PEG-protein conjugates exhibited immunogenicity higher than those of both methoxy-and hydroxyl-terminated PEG-protein conjugates.”
Peter, S., Khwaza, V., Alven, S., Naki, T., & Aderibigbe, B. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020190 · Cited by 21
“However, in an animal study involving rabbits, Sherman et al. [32] investigated how the methoxy group (-OCH 3 ) affects immune responses to proteins that are conjugated with mPEG.”
Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines
Shiraishi, K. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2538423 · Cited by 24
“Indeed, previous research reported that the use of butoxy groups at PEG termini increased both the antigenicity and the immunogenicity of PEG [98,99].”
Discrete polyethylene glycol derivatives as a potent impetus for next-generation biomedicines
Cen, J., Hou, M., & Liu, S. (2023) · Giant · doi:10.1016/j.giant.2023.100169 · Cited by 18
Pharmacokinetics considerations for gout treatments
Richette, P., Frazier, A., & Bardin, T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.915027 · Cited by 16
Song, J., Su, D., Wu, H., & Guo, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060798 · Cited by 21
Liu, J., Wang, Z., He, J., Wang, G., Zhang, R., & Zhao, B. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmu068 · Cited by 15
“Several studies have claimed that the PEG moiety of PEGylated therapeutic proteins itself might be immunogenic and could induce anti-PEG antibodies [27].”
BackgroundEnsminger, Y., Rashmi, R., Karimov, M., Nölte, G., Hafke, M., Schmitt, A., Díaz‐Oviedo, C. D., Köbberling, J., & Haag, R. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202500428 · Cited by 20
Liang, Y., Zhang, C., Wei, H., Du, H., Zhang, G., Yang, Y., Zhang, H., Gong, H., Li, P., Song, F., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.922304 · Cited by 14
“Several reports showed that anti-PEG antibodies accelerated the clearance of PEG-conjugated proteins and contribute to the loss of efficacy of PEG conjugates (25, 26).”
BackgroundSoshee, A., Zürcher, S., Spencer, N. D., Halperin, A., & Nizak, C. (2013) · Biomacromolecules · doi:10.1021/bm401360y · Cited by 17
PEGylated Nanoparticles as a Versatile Drug Delivery System
Mohapatra, P., Singh, D., & Sahoo, S. K. (2021) · Wiley eBooks · doi:10.1002/9783527832095.ch10 · Cited by 17
Maiti, D., Yokoyama, M., & Shiraishi, K. (2024) · ACS Omega · doi:10.1021/acsomega.4c02655 · Cited by 14
Krishna, M., Palme, H., Duo, J., Lin, Z., Corbett, M. J., Dodge, R. W., Piccoli, S. P., Myler, H. A., Pillutla, R. C., & Desilva, B. S. (2015) · Bioanalysis · doi:10.4155/bio.15.112 · Cited by 13
Lipid-Based Nanopharmaceuticals in Antimicrobial Therapy
Škalko-Basnet, N., & Vanić, Ž. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-41625-2.00005-3 · Cited by 21
Induction of Anti-PEG Immune Responses by PEGylation of Proteins
Shimizu, T., Ishima, Y., & Ishida, T. (2020) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.19-00187-5 · Cited by 14
Bivi, N., Swearingen, C., Shockley, T. E., Sloan, J. H., Pottanat, T. G., Carter, Q. L., Hodsdon, M. E., Siegel, R. W., & Konrad, R. J. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112856 · Cited by 13
Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities
Mihindukulasooriya, S. P., Wang, Z., Li, S., Saini, A., Wilson, K., Plebanski, M., Kent, S. J., & Ju, Y. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115925 · Cited by 20
Zeng, Y., Xu, T., Hou, X., Liu, J., Liu, C., Chang, Z., Fang, J., & Chen, D. (2023) · ACS Applied Polymer Materials · doi:10.1021/acsapm.3c00390 · Cited by 12
Critical appraisal of the role of pegloticase in the management of gout
Ea, H., & Richette, P. (2012) · PubMed Central · doi:10.2147/oarrr.s1743 · Cited by 12
“Much of the immunogenicity of PEG-protein conjugates with mPEG is due to the methoxy groups.(12) In a Phase II multidose open-label study, intravenous pegloticase, 8 mg every 2 weeks for 12 to 14 weeks, was the most effective in lowering SU, with the highest proportion of responders (87.”
Ding, T., Fu, J., Yang, M., Zhang, Z., Ma, Y., Wu, E., Guo, Z., Lin, S., Wang, S., Liu, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.21.619346 · Cited by 11
Ishima, Y., Yamazaki, N., Chuang, V. T. G., Shimizu, T., Ando, H., & Ishida, T. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00389 · Cited by 10
Immunogenicity Assessment of Biosimilars: A Multidisciplinary Perspective
Chamberlain, P., & Kurki, P. (2018) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-99680-6_19 · Cited by 10
Humphries, J., Warne, N. M., Feeney, O. M., Thurecht, K. J., & Kempe, K. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114838 · Cited by 11
Emerging Approaches for Enabling RNAi Therapeutics
Mallick, A. M., Tripathi, A., Mishra, S., Mukherjee, A., Dutta, C., Chatterjee, A., & Roy, R. S. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200451 · Cited by 9
Polyethylene glycol: structure, properties, and biomedical applications
Sankaranarayanan, S. A., Murugappan, S., Eswar, K., Padmakumar, A., & Rengan, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95233-0.00009-1 · Cited by 10
Zhang, K., Li, M., Sui, D., Zhao, J., She, Z., Ding, K., Shang, X., Du, Z., Wang, N., Lu, Y., et al. (2025) · Nanoscale · doi:10.1039/d5nr01680k · Cited by 12
Chen, X., Luo, Z., Hu, Z., Sun, D., He, Y., Lu, J., Chen, L., & Liu, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116082 · Cited by 8
Tran, T. H., Nguyen, H. T., Yong, C. S., Truong, D. H., & Kim, J. O. (2019) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.532 · Cited by 7
Revealing the Immunogenic Risk of Polymers
Li, B., Yuan, Z., Hung, H., Ma, J., Jain, P. R., Tsao, C., Xie, J., Zhang, P., Lin, X., Wu, K., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201808615 · Cited by 7
Ohashi, M., Tamura, A., & Yui, N. (2021) · Langmuir · doi:10.1021/acs.langmuir.1c01894 · Cited by 7
Guo, Y., Zhang, J., Mei, R., Tang, Z., Liu, M., Weng, X., Shi, M., & Yin, L. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117083 · Cited by 7
RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases
Xia, B., Shaheen, N., Chen, H., Zhao, J., Guo, P., & Zhao, Y. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107659 · Cited by 8
“Studies have suggested changing the terminal group of PEG from methoxyl to hydroxyl can reduce the immunogenicity [259].”
Debulking the Urate Load to Feel Better
Richette, P. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.120427 · Cited by 6
Lipid nanoparticle-assisted mRNA therapy for cancer treatment
Kim, H.-J., Le, N. D., Oh, H.-J., Kim, B., Yoo, E., Kim, J., & Yim, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0247029 · Cited by 5
Novel drug discovery strategies for gout
Richette, P., & Garay, R. P. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.742061 · Cited by 5
“[20] recently reported a way to reduce the Ribose-5-P”
BackgroundPEG–protein conjugates; regulatory requirements for characterization
Bossard, M. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64081-9.00007-3 · Cited by 5
Carbon dioxide sorption and melting behaviour of mPEG-alkyne
López, S., Ramos, M. J., García-Vargas, J. M., García, M. T., Rodríguez, J. F., & Gracia, I. (2021) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2021.105182 · Cited by 5
Lee, S. Y., Lee, S. H., Tor, Y. S., Yong, P. V. C., & Ho, K. L. (2026) · BioNanoScience · doi:10.1007/s12668-025-02384-6 · Cited by 5
Watumlawar, E. C., & Park, B. (2024) · ACS Omega · doi:10.1021/acsomega.4c01267 · Cited by 4
Zhang, X., Yang, K., Guo, J., Chang, Y., Zou, X., & Fang, C. (2025) · Journal of Membrane Science · doi:10.1016/j.memsci.2025.123982 · Cited by 4
Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery
Lam, J. H., Sinsinbar, G., Loo, S. Y., Chia, T. W., Lee, Y. J., Fong, J. Y., Chia, Y. E., Penna, R. R., Liu, S., Pascolo, S., et al. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.4c01820 · Cited by 5
Vojdani, A., & Vojdani, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-17777-6 · Cited by 4
“…as BSA (bovine serum albumin) or KLH (keyhole limpet hemocyanin) are conjugated with multiple PEG molecules and injected into rabbits, they generate antibodies with over 1000-fold higher affinity for multiple PEGs than to hydroxyl-PEG (HO-PEG)-protein that does not contain any methoxy group 59 .”
Abd-Ellah, H. S., Mudududdla, R., Carter, G. P., & Baell, J. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051530 · Cited by 4
“The potential immunogenicity of the PEG moiety has recently been reported to increase the hydrophobicity of PEG end group [67].”
Nemtarev, A. V., Mironov, V. F., Aniskin, A. S., Baranov, D. S., Krivolapov, D. B., Мусин, Р. З., & Василевский, С. Ф. (2016) · Russian Chemical Bulletin · doi:10.1007/s11172-016-1452-6 · Cited by 4
Zhang, C., Fan, K. C., Luo, H., Cheng, Y., Lu, Y., Zheng, J., Chen, Z., Xue, J., Zhao, Q., Zhang, M., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116892 · Cited by 4
Challenges and Risks of Nanotechnology in Medicine: An Immunologist's Point of View
Szebeni, J. (2016) · Wiley eBooks · doi:10.1002/9783527692057.ch7 · Cited by 4
AFM-Based Single-Molecule Force Spectroscopy of PEG–Anti-PEG Antibody Interactions
Latag, G. V., Tahara, H., Katase, A., Maeda, S., Liu, Y., Kakuta, Y., Teramoto, T., Mori, T., & Hayashi, T. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c01967 · Cited by 3
Ding, T., Fu, J., Yang, M., Zhang, Z., Ma, Y., Wu, E., Guo, Z., Lin, S., Wang, S., Liu, X., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c07672 · Cited by 15
Synthesis and Operating Optimization of the PEG Conjugate via CuAAC in scCO2
López, S., Gracia, I., García, M. T., Rodríguez, J. F., & Ramos, M. J. (2021) · ACS Omega · doi:10.1021/acsomega.0c05466 · Cited by 5
Davis, E., Caparco, A. A., Jones, E., Steinmetz, N. F., & Pokorski, J. K. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02726k · Cited by 3
Site-specific PEGylation of interferon beta-1b
Nairn, N. W., Grabstein, K. H., Shanebeck, K. D., Li, G., & Wang, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64081-9.00015-2 · Cited by 3
Opportunities in Therapeutic mRNA Stabilization: Sequence, Structure, Adjuvants and Vectors
Choe, J. A., Burger, J. C., Jones, J. M., Panjla, A., & Murphy, W. L. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202400537 · Cited by 4
Fu, J., Ding, T., Li, G., Wu, E., Wei, A., Liu, M., Wang, B., & Zhan, C. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101609 · Cited by 5
“Additionally, the use of detergents and blocking regents has been shown to affect detection sensitivity, especially Tween-based detergents [35].”
Dreier, P., Bockhard, C., Seibel, D., Soltwedel, О., Matthes, R., Linden, G. M., Schmidt, J., Göbel, D., Endres, T., Scheiger, J. M., et al. (2026) · Chemical Science · doi:10.1039/d6sc00169f · Cited by 4
Polymer conjugation benefits proteins beyond simply extended half-life
Cao, L., Yang, C., & Zeng, Z. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.05.053 · Cited by 3
Santelli, J., Heble, A. Y., Endsley, C., Woodward, A., Hafeez, N., Winick, N. J., & Lux, J. (2025) · Small Methods · doi:10.1002/smtd.202500945 · Cited by 3
Liu, Y., Yu, N., Khosraviani, M., & Wakshull, E. (2020) · Bioanalysis · doi:10.4155/bio-2020-0191 · Cited by 3
Luppi, B. T., Primrose, W. L., & Hudson, Z. M. (2024) · Angewandte Chemie · doi:10.1002/ange.202400712 · Cited by 1
Rezvantalab, S., Mihandoost, S., Pallares, R. M., & Kiessling, F. M. (2025) · ACS Omega · doi:10.1021/acsomega.5c04425 · Cited by 1
Dyleski, L. A., Wang, Y., Seletskaia, E., Walus, L. R., Caiazzo, T., Joyce, A. P., Baltrukonis, D. J., & Lepsy, C. S. (2025) · Journal of Immunological Methods · doi:10.1016/j.jim.2025.113917 · Cited by 1
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Terminal end groups of poly(ethylene glycol) reduce antigenicity
Shiraishi, K. (2025) · Polymer Journal · doi:10.1038/s41428-025-01128-3 · Cited by 2
From PEG to randomized PEG: a macromolecular strategy tackling PEG immunogenicity
Schmidt, J., Bockhard, C., Simon, L., Linden, G. M., Scheiger, J. M., & Frey, H. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115943 · Cited by 5
Early candidate selection and formulation development
Razinkov, V. I., & Kleemann, G. R. (2016) · Elsevier eBooks · doi:10.1016/b978-1-907568-63-3.00002-5 · Cited by 1
Bioconjugates Based on Poly(Ethylene Glycol)s and Polyglycerols
Shenoi, R. A., Gao, F., ul‐haq, M. I., & Kizhakkedathu, J. N. (2014) · Wiley eBooks · doi:10.1002/9781118775882.ch2
PEGylation technology for the drug development
Ikeda, Y. (2016) · Drug Delivery System · doi:10.2745/dds.31.268
Characteristics, evaluation and suppression of anti-poly(ethylene glycol) antibody
Shimizu, T., & Ishida, T. (2016) · Drug Delivery System · doi:10.2745/dds.31.300
Immune Responses to PEGylated lipoplexes, a review
Qelliny, M. R., Fathalla, Z. M. A., Hussein, A. K., & Khaled, K. (2021) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2021.96968.1140
“The second one is backbone-specific antibodies that bind to both PEG diol and methoxy group with no difference[124].”
BackgroundIntroduction to the Chemical Modification of Proteins
(2014) · CRC Press eBooks · doi:10.1201/b16867-2
Wang, Y. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1553
Sayed, M., Emam, S. E., El-Garhy, O. H., Sarhan, H. A., & Kamal, A. (2023) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2023.184283.1176 · Cited by 1
Advances in synthesis and nanodelivery systems of PEGylated peptide drugs
Liu, J., Yuan, H., Xu, J., Dong, Y., Shi, F., & Li, F. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2025-0100
Critical appraisal of the role of pegloticase in the management of gout
Ea, H., & Richette, P. (2012) · DOAJ (DOAJ: Directory of Open Access Journals)
Haykır, N. I., Kosaoğlu, H., Tuncel, A., & Çelebi, S. S. (2026) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2026.103987
Fiedler, B. M., Galley, C., Štrimaite, M., Cheng, N. M., Mahmoudi, N., Feng, Z.-P., Kalber, T. L., Martinez-Bravo, M.-J., Morris, C. G., Lam, J. K. W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.26.708093
Bondia, A. M. (2013) · theses.fr (ABES) · doi:10.70675/2694eb23z3120z4665za3e9z32d07c922458
Suppressive Immune Response of Poly(sarcosine) Conjugated Proteins: PSARylation
Tsuda, N., Okuno, Y., Yasuda, A., Ando, M., & Iwasaki, Y. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00159 · Cited by 1
Degey, M., Pedergnana, S., Évrard, B., Piel, G., Debuigne, A., & Berger, M. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2699381
Müller, V., Schmidt, J., Matthes, R., Dreier, P., Schüttner, S., Bros, M., & Frey, H. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.6c01182
Critical appraisal of the role of pegloticase in the management of gout
Ea, H., Ea, H., & Richette, P. (2012) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s17431
Fiedler, B. M., Galley, C., Štrimaite, M., Cheng, N. M., Mahmoudi, N., Feng, Z.-P., Kalber, T. L., Martinez-Bravo, M.-J., Morris, C. J., Lam, J. K. W., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c11940
Metadata
- Authors
- Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Saifer, M. G. P.
- Affiliations
- Edison Pharmaceuticals (United States) (US)
- Corresponding author
- Sherman, Merry R.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-03-07
- Volume
- 23
- Issue
- 3
- Pages
- 485-499
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- PMC
- PMC3309606
- OpenAlex
- W64311466
- Cited by
- 185
- References
- 53
- Citations by year
- 2026: 14 · 2025: 26 · 2024: 13 · 2023: 14 · 2022: 16 · 2021: 13 · 2020: 13 · 2019: 12 · 2018: 10 · 2017: 7 · 2016: 12 · 2015: 12 · 2014: 8 · 2013: 8 · 2012: 7
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Bioconjugate Chemistry (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- anti-PEG antibodies, PEGylation, immune response, antibody affinity, human serum albumin, interferon-alpha, uricase, superoxide dismutase
- MeSH terms
- Animals, Enzyme-Linked Immunosorbent Assay, Humans, Polyethylene Glycols, Proteins, Rabbits, Interferon-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.